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Abstract
To understand the status of oropharyngeal yeast colonization in human immunodeﬁciency virus (HIV) -infected outpatients in the era
of highly active antiretroviral therapy (HAART), we conducted a prospective, cross-sectional study from October 2009 to January
2010 at a medical centre in southern Taiwan. Fungal cultures of the oropharyngeal swabs were performed on 327 enrolled patients.
At enrolment, 258 (79%) patients had been receiving HAART, and 42 (12.8%), 73 (22.3%) and 212 (64.8%) patients had CD4 cell
counts £200, 201–350, and >350 cells/mm3, respectively. Oral yeast colonization was detected in 193 (59%) patients, among whom
157 (81.3%), 25 (13.0%), and 11 (5.7%) were colonized by a single, two and more than two species, respectively. Multivariate analysis
showed that receipt of efavirenz-containing regiments and CD4 cell counts >200 cells/mm3 were associated with lower risks of oral
yeast colonization, while intravenous drug users were at a higher risk. Among the 241 isolates recovered, Candida albicans accounted
for 69.7%, followed by C. dubliniensis (9.5%), C. glabrata (8.3%), C. tropicalis (3.3%), C. intermedia (2.1%), C. parapsilosis (1.7%), and 11
other species (5.4%). Overall, 230 (95.4%), 236 (97.9%) and 240 (99.6%) isolates were susceptible to ﬂuconazole, voriconazole and
amphotericin B, respectively. In conclusion, colonization by C. dubliniensis has emerged in recent years. In addition to a CD4 cell
count £200 cells/mm3, which is a known risk factor for oropharyngeal yeast colonization in HIV-infected patients that was identiﬁed
in our previous studies, two risk factors, non-receipt of efavirenz-based combinations and intravenous drug use, were ﬁrst identiﬁed
in the present study. Fluconazole remained effective in vitro against the yeasts colonizing the oropharynx in this population.
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Introduction
Oropharyngeal colonization by Candida species in human
immunodeﬁciency virus (HIV) -infected patients [1–4] may
evolve to oro-oesophageal candidiasis during progressive
immunodeﬁciency [5], which can subsequently hamper the
nutritional intake of patients and increase the medical cost
of patient management. In HIV-infected patients, Candida
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albicans is themain species of colonization [3,6]. However, colo-
nization by C. dubliniensis has increased in recent years [3,7,8].
Oral candidiasis usually responds to effective antifungal agents,
but the antifungal susceptibility proﬁle varies with Candida spe-
cies andprevious useof antifungal agents [9].
In Taiwan, the overall prevalence of HIV infections
increased from 0.16& in 2001 to 0.89& in 2010 [10]. The
government has been providing free highly active antiretro-
viral therapy (HAART) to HIV-infected patients in Taiwan
since 1997. Consequently, the number of patients receiving
HAART has increased in the recent decade. Although the
risk factors and species distribution of oropharyngeal yeast
colonization in HIV-infected patients had been discussed in
our previous studies conducted in 1999–2002 and 2005
[1,6], the effect of different antiretroviral agents on coloniza-
tion was not addressed. Moreover, there was a dramatic
increase in the population of HIV-infected intravenous drug
users (IDUs) between 2004 and 2006 in Taiwan [11]. Facing
a changing epidemiology, we conducted another survey
between 2009 and 2010 to investigate the risk factors and
species distribution of oropharyngeal yeast colonization in
HIV-infected patients and the antifungal susceptibility of iso-
lates recovered from the survey, with the hope of providing
useful information to assist the population.
Materials and Methods
Study population and data collection
This prospective cross-sectional study was conducted from
October 2009 to January 2010. The study was approved by
the Human Experiment and Ethics Committee of National
Chen-Kung University Hospital, a medical centre in southern
Taiwan. HIV-infected patients at the outpatient infectious dis-
eases clinic were enrolled after informed consents had been
obtained. A standardized data collection form was used to
retrieve demographic characteristics (age, gender and types
of HIV transmission), known period of HIV infection, the
underlying medical conditions, and information within the
6 months prior to enrolment, including the presence of oral
thrush, the latest CD4 cell counts and HIV viral loads, his-
tory of hospitalization and residence in jails or rehabilitation
centres, and recent receiving of antibacterial/antifungal treat-
ments for ‡ 1 day, and antiretroviral agents for ‡ 2 weeks
within 3 months of enrolment.
Sample collection and fungal cultures
Oropharyngeal swabs were obtained using a dry sponge
swab (EZ Culturette; Becton Dickinson, Sparks, MD).
All swabs were maintained at room temperature and
transported to the central laboratory at the National Health
Research Institutes within 24 h. The swabs were then
streaked onto Chromagar Candida agar medium (CHROMa-
gar, Paris, France). All plates were incubated at 30C. Three,
if present, colonies from each plate were selected for further
analyses. Additional colonies were selected from the plates
when there was more than one morphotype present. All iso-
lates were subjected to the VITEK Yeast Biochemical Card
(bioMe´rieux; Marcy l’Etoile, France) for species identiﬁcation.
When the Yeast Biochemical Card identiﬁcation probability
was less than 90% or when uncommon species were
reported, the sequences of the internal transcribed spacer
(ITS) region and the D1/D2 region of ribosomal DNA were
used for species identiﬁcation. The ITS regions were ampli-
ﬁed using the primers ITS1, 5¢-TCCGTAGGTGAACCT
GCGG-3¢ and ITS4 5¢-TCCTCCGCTTATTGATATGC-3¢,
and the D1/D2 regions were ampliﬁed using the primers
NL1 5¢-GCATATCAATAAGCGGAGGAAAAG-3¢ and NL4
5¢-GGTCCGTGTTTCAAGACGG-3¢ [12,13].
Antifungal susceptibility tests
The MICs of antifungal drugs were determined according to
the guidelines of M27-A3 recommended by the Clinical and
Laboratory Standards Institute [14]. The RPMI-1640 medium
(31800–022, Gibco BRL, Carlsbad, CA) was used for the
dilution and growth of the yeast culture. Strains from Ameri-
can Type Culture Collection (ATCC, Manassass, VA), includ-
ing C. albicans (ATCC 90028), C. krusei (ATCC 6258) and
C. parapsilosis (ATCC 22019), were used as the standard
controls. Growth of each isolate was measured by the
Biotrak II plate spectrophotometric reader (Amersham Bio-
sciences, Biochrom Ltd., Cambridge, UK) after incubation at
35C for 48 h.
The MICs for amphotericin B and azoles were deﬁned as
the lowest concentrations capable of preventing any discern-
ible growth and of reducing the turbidity of cells by >50%,
respectively. For amphotericin B, MICs of ‡2 lg/mL were
considered resistant and £1 lg/mL susceptible. For ﬂuconaz-
ole, MICs of ‡64 lg/mL were considered resistant and
£8 lg/mL susceptible. The isolates with MICs in the range of
16–32 lg/mL were referred to as susceptible-dose-depen-
dent. For voriconazole, MICs of ‡4 lg/mL were considered
resistant and £1 lg/mL susceptible [14]. Generally, only one
isolate of each patient was analysed. Nevertheless, when a
patient was colonized by more than one species, one isolate
of each species was included.
Statistical methods
The results were analysed with SPSS software for Windows,
version 12.0. Variables collected in the data collection form
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were tested for association with yeast colonization and
infection. The chi-square test was applied for categorical
variables, and the Student’s t-test for continuous vari-
ables. Logistic regression was applied to assess the inde-
pendent effects of factors found to be signiﬁcant in the
univariate analysis. A p value <0.05 was considered sig-
niﬁcant.
Results
Patients
During the study period, a total of 327 patients were
enrolled. Their demographic data are shown in Table 1. They
were predominantly men (299, 91.4%) and 36 (11%) patients
were IDUs. Overall, 42 (12.8%), 73 (22.3%) and 212 (64.8%)
patients had a CD4 cell count £200, 201–350 and
>350 cells/mm3, respectively. At enrolment, 258 (79%)
patients were receiving HARRT.
Status and risk factors for yeast colonization
Of the 327 patients, 193 (59%) were colonized by yeasts,
among whom 157 (81.3%), 25 (13.0%) and 11 (5.7%) were
by single, two and more than two species, respectively. A
higher proportion of patients with low CD4 cell counts were
colonized by yeasts than those with higher counts (81% in
£200/mm3 versus 56% in >200/mm3, p 0.002). By univariate
analysis, patients who were IDUs, patients who had been
exposed to antibacterial agents, and patients who received
mycostatin oral suspension in the previous 6 months were at
risk for colonization, whereas a CD4 cell count >200 cells/
mm3 and being in receipt of lamivudine or lamivudine/zidovu-
dine, or efavirenz protected patients from colonization. Use
of protease inhibitors (atazanavir or lopinavir/ritonavir) had
no signiﬁcant effect on colonization (p 0.26). By multivariate
analysis, receipt of efavirenz and a CD4 count >200 cells/
mm3 protected patients from colonization, whereas IDUs
were at risk for colonization (Table 1). Furthermore, the
protective effect of efavirenz-based antiretroviral therapy on
TABLE 1. Characteristics of 327 human immunodeﬁciency virus (HIV) -infected patients enrolled for oropharyngeal fungal cul-
tures and predictors of positive culture for yeasts
Characteristic All (n = 327)
Yeast culture Univariate Multivariate
Positive (n = 193) Negative (n = 134) p value p value, OR (95% CI)
Age, years (mean ± SD) 38.7 ± 12.8 39.6 ± 12.7 37.5 ± 13.0 0.146
CD4, cells/mm3 (mean ± SD) 477.8 ± 283.7 455.3 ± 246.5 524.7 ± 325.3 0.013
HIV viral load, log (copies/mm3) (mean ± SD) 2.05 ± 1.27 (n = 324) 2.15 ± 1.32 (n = 190) 1.91 ± 1.19 0.092
Known period of HIV infection, years (mean ± SD) 5.21 ± 3.72 5.32 ± 3.81 5.05 ± 3.61 0.53
No. of subjects with indicated transmission type (%)
Men having sex with men or bisexual 179 (54.7%) 103 (53.4%) 76 (56.7%) 0.574
Heterosexual 101 (30.9%) 57 (29.5%) 44 (32.8%) 0.545
Intravenous drug user 36 (11%) 28 (14.5%) 8 (6%) 0.019* 0.031
2.53 (1.09–5.86)
Males, no. (%) 299 (91.4%) 175 (90.7%) 124 (92.5%) 0.689
CD4 counts >200 cells/mm3, no. (%) 285 (87.2%) 159 (82.4%) 126 (94%) 0.002* 0.002
0.27 (0.12–0.62)
Diabetes mellitus, no. (%) 11 (3.4%) 8 (4.1%) 3 (2.2%) 0.535
Chronic kidney diseases, no. (%) 2 (0.6%) 2 (1%) 0 (0%) 0.515
Hospitalization within 6 months, no. (%) 111 (33.9%) 60 (31.1%) 51 (38.1%) 0.194
Residence in a jail or rehabilitation centre
within 6 months, no. (%)
2 (0.6%) 1 (0.5%) 1 (0.7%) 1
Medications
Antiretroviral therapy within 3 months 258 (78.9%) 146 (75.6%) 112 (83.6%) 0.098
lamivudine/zidovudine 134 (41.0%) 71 (36.8%) 63 (47.0%) 0.068
l zidovudine or lamivudine/zidovudine 136 (41.6%) 72 (37.3%) 64 (47.8%) 0.068
l lamivudine or lamivudine/zidovudine 239 (73.1%) 132 (68.4%) 107 (79.9%) 0.023*
l stavudine 14 (4.3%) 10 (5.2%) 4 (3%) 0.413
l abacavir 96 (29.4%) 53 (27.5%) 43 (32.1%) 0.389
l didanosine 33 (10.1%) 22 (11.4%) 11 (8.2%) 0.36
l efavirenz 101 (30.9%) 45 (23.3%) 56 (41.8%) <0.001* 0.005
0.48 (0.29–0.80)
l nevirapine 18 (5.5%) 10 (5.2%) 8 (6%) 0.808
l atazanavir 21 (6.4%) 15 (7.8%) 6 (4.5%) 0.26
l lopinavir/ritonavir 117 (35.8%) 73 (37.8%) 44 (32.8%) 0.412
l PIa (atazanavir or lopinavir/ritonavir) 21 (6.4%) 15 (7.8%) 6 (4.5%) 0.26
Antibacterials within 6 months 42 (12.0%) 33 (17.1%) 9 (6.7%) 0.007*
Antifungals within 6 months
l ﬂuconazole 6 (1.8%) 6 (3.1%) 0 (0%) 0.085
l amphotericin B 2 (0.6%) 1 (0.5%) 1 (0.7%) 1
l mycostatin oral suspension 10 (3.1%) 10 (5.2%) 0 (0%) 0.006*
*Variables entered in the multivariate analysis.
aPI, protease inhibitor; OR, odds ratio, CI, conﬁdence interval; SD, standard deviation.
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colonization remained signiﬁcant even in a subgroup analysis
of 258 patients receiving HAART. Receipt of efavirenz (OR,
0.474; 95% CI 0.28–0.804; p 0.006) and a CD4 count
>200 cells/mm3 (OR, 0.362; 95% CI 0.139–0.942; p 0.037)
were two negative predictors for colonization based on mul-
tivariate analysis.
As for oral yeast infections, 11 of the 327 patients had
experienced oral thrush in the 6 months before the study
and ﬁve patients had oral thrush at the time of enrolment.
Overall, 15 (4.7%) patients had recent or current oral
thrush. Patients with a CD4 cell count £200 cells/mm3 had a
higher rate of recent or current oral thrush than those with
a CD4 cell count >200 cells/mm3 (28.6% versus 1%,
p < 0.001), and multivariate analysis showed that a CD4 cell
count £200 cells/mm3 was the only independent factor asso-
ciated with the development of oral thrush (OR, 12.8; 95%
CI 1.08–150.4; p 0.043). Among the 193 patients with yeast
colonization, a CD4 cell count £200 cells/mm3 (OR, 9.37;
95% CI 1.48–59.2; p 0.017) and previous exposure to anti-
bacterial agents (OR, 9.9; 95% CI 1.50–65.4; p 0.017) were
the two variables associated with oral thrush based on multi-
variate analysis.
Species distribution and antifungal susceptibility of yeasts
Of the 241 yeast isolates characterized, 12 isolates needed
to be speciated by DNA sequencing of the ribosomal DNA
fragments. Seven isolates, including three C. glabrata, two
C. albicans, one C. guilliermondii and one C. membranifaciens,
were identiﬁed by sequencing the ITS fragments and four
isolates, including one each of C. glabrata, C. inconspicua,
C. membranifaciens and C. tropicalis, were identiﬁed by
sequencing the D1/D2 fragments. The remaining isolate,
Metschnikowia spp., could not be identiﬁed to species level
even using both ITS and D1/D2 sequence. The colonization
species were C. albicans (168, 69.7%), C. dubliniensis (23,
9.5%), C. glabrata (20, 8.3%), C. tropicalis (8, 3.3%), C. interme-
dia (5, 2.1%), C. parapsilosis (4, 1.7%) and Saccharomyces cere-
visiae (3, 1.2%), and others (10, 4.0%) (Table 2). Overall,
Candida species accounted for 97.5% of these isolates. All 15
patients with previous or current oral thrush were colonized
by C. albicans at enrolment, and two were simultaneously
colonized by C. tropicalis, one by C. dubliniensis and one by
C. glabrata.
Patients with C. albicans colonization were signiﬁcantly
younger than those with non-C. albicans yeasts (39.6 versus
43.6 years, p 0.037). Risk factors for C. dubliniensis coloniza-
tion were not identiﬁed. Furthermore, patients colonized
with multiple species were associated with a longer known
period of HIV infection (4.6 versus 3.5 years, p 0.011) and
prior exposure to penicillin derivatives (OR, 9.0; 95% CI
1.28–63.92; p 0.027).
Of the 241 isolates, 230 (95.4%), 236 (97.9%) and 240
(99.6%) isolates were susceptible to ﬂuconazole, voriconaz-
ole and amphotericin B, respectively (Table 2). Seven (2.4%)
and ﬁve (2.1%) isolates, mostly C. albicans (four and three
isolates), were resistant to ﬂuconazole and voriconazole,
respectively. Eight Candida isolates, including six C. albicans
isolates, one C. dubliniensis and one C. glabrata, were recov-
ered from six patients who had received ﬂuconazole for oral
thrush. Of these eight isolates, only the C. glabrata isolate
TABLE 2. Species distribution and antimicrobial susceptibilities of yeasts recovered from the oropharynx of human immuno-
deﬁciency virus-infected patients
Yeast
No. of isolates (%) with indicated minimum inhibitory concentrations (lg/mL)
Total no.
of isolates (%)
Fluconazole Voriconazole Amphotericin B
S, £8 SDD, 16–32 R, ‡64 S, £1 SDD, 2 R, ‡4 S, ‡1 R, ‡2
Candida albicans 163 1 4 (2.4) 165 0 3 (1.8) 168 0 168 (69.7)
Candida dubliniensis 22 0 1 (4.3) 22 0 1 (4.5) 22 1 (4.3) 23 (9.5)
Candida glabrata 19 1 0 20 0 0 20 0 20 (8.3)
Candida tropicalis 7 0 1 (12.5) 7 0 1 (12.5) 8 0 8 (3.3)
Candida intermedia 5 0 0 5 0 0 5 0 5 (2.1)
Candida parapsilosis 4 0 0 4 0 0 4 0 4 (1.7)
Saccharomyces cerevisiae 3 0 0 3 0 0 3 0 3 (1.2)
Candida famata 1 0 0 1 0 0 1 0 1 (0.4)
Candida galeiformis 0 1 0 1 0 0 1 0 1 (0.4)
Candida guilliermondii 1 0 0 1 0 0 1 0 1 (0.4)
Candida inconspicua 0 1 0 1 0 0 1 0 1 (0.4)
Candida krusei 0 0 1 (100) 1 0 0 1 0 1 (0.4)
Candida lusitaniae 1 0 0 1 0 0 1 0 1 (0.4)
Candida rugosa 1 0 0 1 0 0 1 0 1 (0.4)
Cryptococcus neoformans 1 0 0 1 0 0 1 0 1 (0.4)
Kodamaea ohmeri 1 0 0 1 0 0 1 0 1 (0.4)
Metschnikowia spp. 1 0 0 1 0 0 1 0 1 (0.4)
Total 230 (95.4) 4 (1.7) 7 (2.9) 236 (97.9) 0 (0) 5 (2.1) 240 (99.6) 1 (0.4) 241 (100)
S, susceptible; SDD, susceptible-dose-dependent; R, resistant.
488 Clinical Microbiology and Infection, Volume 18 Number 5, May 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 485–490
had increased MICs of ﬂuconazole (8 lg/mL) and voriconaz-
ole (0.25 lg/mL) whereas the other seven isolates remained
susceptible to ﬂuconazole (MIC £1 lg/mL) and voriconazole
(£0.03 lg/mL), irrespective of previous ﬂuconazole exposure.
Discussion
The demographic and microbiological characteristics of oro-
pharyngeal yeast colonization in HIV-infected and non-HIV-
infected populations in our previous reports [1,6,15] and the
present study were compared. With the introduction of HA-
ART, the mean CD4 cell counts gradually increased over
time (from 208 cells/mm3 in 1999–2002 to 478 cells/mm3 in
2009–2010, respectively), which coincided with a reduced
rate of patients with recent or current oral thrush (from
12.9% in 1999–2002 to 4.7% in 2009–2010). There were
more HIV-infected IDUs enrolled in the present study. Previ-
ous studies have found the rate of oral Candida colonization
among HIV-infected individuals to range from 44 to 82.8%
[1–4]. In our earlier surveys, more than half of HIV-infected
patients were colonized by yeasts [1,6] compared with only
15.2% of the healthy individuals in 2007 [15]. These ﬁndings
suggested that HIV-infected patients are at risk for oropha-
ryngeal yeast colonization, and this continues despite wide
use of HAART. Among the isolates from HIV-infected
patients, 87% in 1999–2002 [6] and 70% in the present study
were C. albicans. Hence, the prevalence of non-albicans Can-
dida species has indeed increased in the past decade.
Clinical information about the effects of different antiret-
roviral agents on the risk of oropharyngeal yeast colonization
or infection is limited. In 2000, HIV protease inhibitors were
the ﬁrst to be associated with a lower rate of oropharyngeal
Candida colonization and candidiasis [16]. The positive impact
of protease inhibitors has been attributed to a better immu-
nological function with their use, or with their antifungal
activity resulting from the similar structure of Candida-
secreted aspartic protease with the targeted protein, i.e. HIV
aspartic protease [17]. However, such an effect of protease
inhibitors was not found in the present study as well as in
another recent study [2]. Instead we found that receipt of an
efavirenz-containing regimen was signiﬁcantly associated with
a lower frequency of oropharyngeal yeast colonization both
in all enrolled patients and in patients receiving HAART. This
is the ﬁrst study showing the potential effect of efavirenz on
oropharyngeal yeast colonization. Despite the statistical sig-
niﬁcance of efavirenz on reduced colonization, further clinical
investigations involving more patients to determine the
impact of the drug on colonization and in vitro antifungal
activity are warranted.
In our previous study conducted in 2005 [1], we found
that all six IDUs were colonized by yeasts and had a CD4
count of >450 cells/mm3. This observation suggested that
IDUs may be at risk for yeast colonization. In the present
study, we were able to reach a statistically signiﬁcant associa-
tion between IDU and yeast colonization. An earlier report
had a similar ﬁnding, showing a higher prevalence of Candida
lesions and oral yeast colonization among the HIV-infected
IDU group than the HIV-infected heterosexual and homosex-
ual groups [18]. Furthermore, studies showed that IDUs,
regardless of their HIV serostatus, were more likely than
homosexual men to present with oral candidiasis [19–21].
Several factors of the lifestyle, access to health care, and the
hygiene conditions of the oral cavity before HIV infection,
inﬂuenced the development of oral lesions in HIV-infected
populations [20]. Whether those same factors contribute to
oropharyngeal yeast colonization needs to be examined.
Candida albicans was the major species, accounting for
70% of all yeast isolates colonizing the oropharynx of HIV-
infected patients, a ﬁnding similar to previous studies in
which C. albicans accounted for 60–83% of colonized isolates
[3,22,23], although a decreased isolation rate was found
compared with that (87%) of our earlier study during 1999–
2002 [6]. Another shift of species distribution in our studies
was noted in C. dubliniensis, which was not recovered during
1999–2002 [6] but was increasingly detected in 2005 (4.3%)
[1] and in the present study (9.5%). Little is known about
the risk factors for C. dubliniensis colonization in HIV-infected
patients, except for a higher prevalence in individuals of
European descent (9%) compared with individuals of African
descent (1.5%) in South Africans [24]. Neither did our study
identify the risk factors for C. dubliniensis colonization. The
clinical implication of these ﬁndings remains to be elucidated.
In conclusion, compared with our previous studies, CD4
cell counts £200 cells/mm3 remained as a risk factor for oro-
pharyngeal yeast colonization in HIV-infected patients,
whereas non-receipt of efavirenz-based combinations and IDU
were ﬁrst identiﬁed as another two risk factors in the present
study. The mechanism contributing to the effect of efavirenz
on oropharyngeal yeast colonization needs further investiga-
tion. An increasing proportion of colonization by C. dubliniensis
was also observed during the decade. Three tested antifungal
agents, ﬂuconazole, voriconazole and amphotericin B,
remained effective against >95% of the colonized yeasts.
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